阿托伐他汀联合曲美他嗪治疗冠心病的疗效分析

Analysis of the Efficacy of Atorvastatin Combined with Trimetazidine in the Treatment of Coronary Artery Disease

目的:分析阿托伐他汀联合曲美他嗪治疗冠心病的疗效。方法:选取2019年10月-2020年9月东营市东营区新区医院及河口区河口社区卫生服务中心收治的128例冠心病患者为研究对象,根据随机数字表法分为对照组和观察组,各64例。对照组给予曲美他嗪进行治疗,观察组在对照组基础上服用阿托伐他汀进行治疗。比较两组心功能、血脂、生化指标及心脑血管不良事件发生情况。结果:治疗前,两组左心室舒张末期内径(LVDD)、左室射血分数(LVEF)水平比较,差异无统计学意义(P>0.05);治疗后,两组LVDD水平低于治疗前,LVEF水平高于治疗前,且观察组LVDD水平低于对照组,LVEF水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组甘油三酯(TG)、总胆固醇(TC)水平比较,差异无统计学意义(P>0.05);治疗后,两组TG、TC水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组C反应蛋白(CRP)、同型半胱氨酸(Hcy)水平比较,差异无统计学意义(P>0.05);治疗后,两组CRP、Hcy水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组心脑血管不良事件总发生率低于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀及曲美他嗪对冠心病的治疗效果较好,可改善心功能,降低血脂,对患者康复具有重要意义。

Objective:To analyze the efficacy of atorvastatin combined with trimetazidine in the treatment of coronary artery disease.Methods:128 patients with coronary heart disease who attended the hospital from October 2019 to September 2020 were selected as study subjects,and were divided into control and observation groups according to the random number table method,with 64 cases each.The control group was given trimetazidine for treatment,and the observation group was treated with atorvastatin on the basis of the control group.The cardiac function,blood lipids,biochemical indexes and the occurrence of cardiovascular and cerebrovascular adverse events were compared between the two groups.Results:Before treatment,there were no statistically significant differences in the levels of left ventricular end-diastolic diameter(LVDD)and left ventricular ejection fraction(LVEF)between the two groups(P>0.05).After treatment,the LVDD levels in both groups were lower than those before treatment,and the LVEF levels were higher than those before treatment.And the LVDD level of the observation group was lower than that of the control group,and the LVEF level was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the levels of triacylglycerol(TG)and total cholesterol(TC)in the two groups(P>0.05).After treatment,TG and TC levels in both groups were lower than before treatment,and the observation group was lower than the control group.The difference was statistically significant(P<0.05).Before treatment,the levels of C-reactive protein(CRP)and homocysteine(Hcy)in the two groups were compared,and the differences were not statistically significant(P>0.05).After treatment,the levels of CRP and Hcy in both groups were lower than those before treatment,and the observation group was lower than the control group.The difference was statistically significant(P<0.05).The total incidence of cardiovascular and cerebrovascular adverse events in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Atorvastatin and trimetazidine are more effective in the treatment of coronary heart disease,which can improve cardiac function and reduce blood lipids,and are important for patients’recovery.